NeoGenomics (NEO) Q4 2025 earnings review
Strong Clinical Execution Masks Pharma Weakness
NeoGenomics ended FY25 with momentum, delivering 11% YoY revenue growth in Q4 ($190M) and a 36% reduction in Net Loss. The core Clinical business is firing on all cylinders, driven by a 23% surge in Next-Generation Sequencing (NGS) revenue and higher average unit prices. However, the Non-Clinical (Pharma) segment remains a significant drag due to macro headwinds. With the RaDaR patent litigation finally resolved, management issued confident FY26 guidance projecting ~10% top-line growth and ~30% Adjusted EBITDA expansion.
🐂 Bull Case
The resolution of the RaDaR ST patent litigation removes a major uncertainty, paving the way for the clinical launch of their MRD (Minimal Residual Disease) assay—a potential $20B+ market opportunity.
Average revenue per test rose 5% to $488. This proves the strategy of shifting mix toward high-margin NGS tests (up 23%) is working, decoupling revenue growth from pure volume reliance.
🐻 Bear Case
Non-clinical revenue continues to shrink due to biotech funding constraints. Management visibility here remains low (historically <1 quarter), creating a persistent headwind against clinical gains.
Despite EBITDA improvements, the company remains GAAP unprofitable (Net Loss $10M in Q4). With $108M lost in FY25, the path to genuine GAAP profitability remains distant.
⚖️ Verdict: 🟢
Bullish. The core Clinical engine is strong enough to carry the company despite the Pharma recession. With the legal cloud lifted and consistent EBITDA execution (up 4 quarters in a row), the setup for FY26 is constructive.
Key Themes
NGS: The Growth Engine
Accelerating. Next-Generation Sequencing (NGS) revenue grew 23% in Q4 and 22% for the full year, significantly outpacing the broader market. This segment now accounts for ~33% of clinical revenue. The launch of PanTracer and the imminent RaDaR ST launch position this as the primary driver for FY26.
RaDaR ST Clinical Launch
With the patent litigation resolved, the company is preparing the clinical launch of RaDaR ST (MRD assay). While FY26 contribution is expected to be 'modest,' this opens access to a $20B+ addressable market and is critical for 2027+ valuation multiples.
Non-Clinical (Pharma) Weakness
Stable Negative. The Pharma services business remains depressed due to macro trends in biotech funding. In previous quarters, this segment declined >25%. While Q4 consolidated revenue beat expectations, this segment prevents a 'blowout' quarter and remains an anchor on overall growth rates.
Margin Expansion & Cost Control
Accelerating. Adjusted Gross Margin (excluding Pathline noise) remains robust. More importantly, Adjusted EBITDA grew 13% to $13M in Q4. FY26 guidance suggests a further ~30% expansion in EBITDA to ~$56M midpoint, demonstrating operational leverage even with the Pharma drag.
Cash Preservation
Stable. Cash ended at $160M, down from $367M a year ago, primarily due to the repayment of $201M in convertible notes earlier in FY25. Operating cash flow turned positive ($5.2M for FY25), a critical turnaround from cash burn in prior years, reducing immediate liquidity risks.
Other KPIs
Up 5% YoY. Accelerating mix shift. This metric confirms that volume growth is not coming at the expense of pricing; rather, customers are adopting higher-value NGS tests.
Beat guidance. Original FY25 guidance (mid-year) was $41-$44M; landed at high end despite Pharma headwinds. Represents a $3M improvement over FY24.
Stable. Expenses were effectively flat YoY despite 11% revenue growth. This discipline is the primary driver of the narrowing net loss.
Guidance
Stable. Implies 9-10% YoY growth, consistent with FY25's 10% growth. This suggests management sees the current momentum as sustainable but is not factoring in a massive immediate spike from RaDaR ST.
Accelerating. Implies ~27-31% YoY growth. This demonstrates significant operating leverage as the Clinical volume continues to scale against a fixed cost base.
Accelerating improvement. Midpoint implies a ~48% reduction in Net Loss compared to FY25 ($(108)M). While still unprofitable on a GAAP basis, the trajectory toward breakeven is speeding up.
Key Questions
Pharma Segment Visibility
The non-clinical segment has been a drag for four quarters. Do you see a bottom forming in 2026, or should investors model a continued 15-20% decline for this segment?
RaDaR ST Commercial Ramp
With litigation resolved, what is the specific timeline for securing reimbursement coverage for RaDaR ST, and when will it become a material revenue contributor (e.g., >5% of sales)?
Pathline Accretion
Pathline was dilutive to margins in 2025. Is the integration complete enough for this asset to be accretive to Adjusted EBITDA in Q1 2026?